So long as COVID-19 continues to pose a high risk to patients in the absence of an effective treatment or vaccine, it is crucial to collect large amounts of high-quality data on this virus. Harmonization of data is needed in order to facilitate the rapid analysis of COVID-19 characteristics and support evidence-based decision making in clinical practice. COVID-19 data are currently fragmented and siloed across poorly interoperable systems. Therefore, a substantial level of curation is required to ensure data are relevant and of high quality.
The HARMONY Alliance, in close collaboration with the European Hematology Association (EHA), organized a webinar about 'the power of integrating harmonized COVID-19 patient data in hematology research' on June 4, 2020.
Watch the webinar recording:
Webinar topics, speakers and moderator
The HARMONY Alliance is a public-private partnership for Big Data in Hematology, established in January 2017. Our mission is to unlock and spread valuable knowledge on hematologic malignancies (blood cancers) among a large number of stakeholders. The ultimate goal of HARMONY is to harness and mine Big Data to speed up the development of improved treatments and treatment strategies for patients.
We currently have 53 Partners and 41 Associated Members from across 17 European countries, including 9 pharmaceutical companies and 7 European Patient Umbrella Organizations. The HARMONY Alliance is funded by the Innovative Medicines Initiative (IMI).
HARMONY takes action to manage COVID-19
Receive the latest news. Click here to subscribe!